Do You Need a Prescription for GLP-1 Medication?

Yes. In the United States, GLP-1 medications are prescription drugs, and federal law allows a prescription drug to be dispensed only on the prescription of a practitioner licensed by law (21 U.S.C. 353(b)(1)). That covers the FDA-approved GLP-1 medications made with semaglutide or tirzepatide, and it covers compounded semaglutide and tirzepatide, which a pharmacy may prepare only for an identified patient on a valid prescription order. A product offered online with no prescription is, by that fact, not being sold as the prescription medicine: it is a supplement, a patch, a vial labeled for research, or an illegally marketed drug of the kind the FDA has warned about. This guide sets out what the law says, how to recognize the products sold around it, and what a legitimate prescription involves. It ends with the prescription step at Majesta Health, where a licensed physician decides and no prescription is guaranteed.

*What this guide covers:*

• Whether you need a prescription for GLP-1 medication in the United States
• What makes a drug prescription-only under federal law
• What the "no prescription" GLP-1 products sold online actually are
• How to tell whether an online pharmacy is legitimate
• Whether a compounded GLP-1 also needs a prescription
• What a legitimate prescription involves
• What happens if the physician says no
• How the prescription step works at Majesta Health

Do you need a prescription for GLP-1 medication in the United States?

Yes. Section 503(b)(1) of the Federal Food, Drug, and Cosmetic Act reaches a drug that "is not safe for use except under the supervision of a practitioner licensed by law to administer such drug," or one whose approved application limits it to that supervision. Such a drug "shall be dispensed only (i) upon a written prescription of a practitioner licensed by law to administer such drug," or on an oral prescription the pharmacist reduces to writing, or as a refill the prescriber authorized (21 U.S.C. 353(b)(1)).

Whether a given medicine sits in that category is a matter of public record. When we queried FDA's Drugs@FDA database through openFDA on September 29, 2026, every marketed product containing semaglutide or tirzepatide carried the marketing status "Prescription." Drugs@FDA listed no over-the-counter product made with either ingredient.

The FDA gives patients the same instruction on its page about unapproved GLP-1 drugs: "Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy." On the same page, the FDA's "unapproved versions" include compounded drugs, and it explains the risk: "unapproved versions do not undergo FDA’s review for safety, effectiveness and quality before they are marketed."

Here is how the products you may see online line up against that rule.

What makes a drug prescription-only under federal law?

Two things decide it. The first is the drug itself. The statute covers a drug that needs a licensed practitioner's supervision because of "its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use," and a drug whose FDA approval limits it to that supervision (21 U.S.C. 353(b)(1)(A) and (B)).

The second is the label. A prescription drug is misbranded if, before it is dispensed, its label "fails to bear, at a minimum, the symbol “Rx only”" (21 U.S.C. 353(b)(4)(A)). FDA's labeling regulation repeats the requirement: "The label of the drug bears: (1) The statement “Rx only”" (21 CFR 201.100(b)(1)).

The statute also says what happens when the rule is broken: "The act of dispensing a drug contrary to the provisions of this paragraph shall be deemed to be an act which results in the drug being misbranded while held for sale." A seller that ships a prescription drug without a prescription is not offering a shortcut. It is doing the thing the statute defines as misbranding.

Two practical checks follow from this.

1. Read the label. A prescription filled for you carries a pharmacy label with the dispensing pharmacy's name and address, the prescriber's name and the date (21 U.S.C. 353(b)(2)).
2. Read the checkout. A site that lets you put a GLP-1 medication in a cart with no prescription on file has already told you what it is.

What are the "no prescription" GLP-1 products sold online?

Four kinds, and none of them is the prescription medicine.

Supplements. A product labeled for "GLP-1 support" and sold as a dietary supplement sits in a different legal category from a drug. The FDA states: "Under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed." It also explains that "Generally, the dietary supplement definition excludes ingredients that are approved as new drugs." Its consumer guidance is plain: "Do not substitute a dietary supplement for a prescription medicine or for the variety of foods important to a healthy diet."

Patches. A patch you can order with no prescription is not a prescription GLP-1 medicine, whatever the name on the box says. When we counted the routes listed on FDA drug labels in the GLP-1 receptor agonist class through openFDA on September 29, 2026, the labels listed subcutaneous and oral routes. None listed a route through the skin.

"Research use" vials. The FDA says it has warned companies over unapproved drugs "falsely labeled “for research purposes” or “not for human consumption.”" It adds: "These products have been sold directly to consumers for human use with dosing instructions." Its advice is direct: "The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health."

Unapproved online sellers. Some websites offer semaglutide or tirzepatide itself without a prescription. The FDA's statement: "FDA monitors the internet for fraudulent or unapproved drugs and has issued warning letters to stop the distribution of illegally marketed semaglutide and tirzepatide." Such drugs, it says, "may be counterfeit" and "could contain too little, too much or no active ingredient at all." The agency "urges consumers to be vigilant when purchasing drugs online and only purchase from state-licensed pharmacies".

The pattern across all four is the same. The missing prescription is not a convenience the seller added. It is the sign that what is for sale is something other than the prescription medicine.

How can you tell whether an online pharmacy is legitimate?

The FDA runs a campaign for exactly this question. Its BeSafeRx program "helps consumers learn about how to safely buy prescription medicines online," and it lists four signs of a safe online pharmacy:

• "Always requires a doctor’s prescription"
• "Provides a physical address and telephone number in the United States"
• "Has a licensed pharmacist on staff to answer your questions"
• "Is licensed with a state board of pharmacy"

Its warning signs start with the mirror image of the first: "Does not require a doctor’s prescription." Another, in the FDA's words, is a site that "Offers deep discounts or prices that seem too good to be true."

The license check is the one that settles it. BeSafeRx links each state's board of pharmacy license database, and its instruction is: "If your online pharmacy is not listed, you should not use that pharmacy."

For telehealth companies the FDA adds its own red flags. Among them is a company that "does not require a screening and prescription by a licensed doctor before providing medicine," or one that "does not have a licensed doctor available to answer questions after you receive your medication."

Put together, the check takes a few minutes:

1. Is a prescription from a licensed prescriber required before anything ships?
2. Is the pharmacy named, and does it appear in your state board of pharmacy's license database?
3. Does the pharmacy give a physical address and telephone number in the United States, and a licensed pharmacist you can ask?
4. Does the company name the physicians who decide, and can you reach one after your medication arrives?
5. Is the price explained in full, with nothing that looks too good to be true?

Does a compounded GLP-1 also need a prescription?

Yes, and in one respect the rule is narrower. Section 503A lets a pharmacy compound a drug that is "compounded for an identified individual patient based on the receipt of a valid prescription order," with the compounding done by "a licensed pharmacist in a State licensed pharmacy or a Federal facility, or (B) a licensed physician" (21 U.S.C. 353a(a)). A compounded GLP-1 preparation is made for one named person on one prescription. A website that sells compounded semaglutide or tirzepatide to anyone who clicks is not describing that arrangement.

Compounded does not mean approved. Compounded medications are not FDA-approved as final products. In the FDA's words: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."

The FDA also states when it considers a compounded drug appropriate: "Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug." That judgment belongs to the prescriber, which is one more reason the prescription cannot be skipped.

Day-to-day oversight of the pharmacy sits mainly with the states: "Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities." That is why the license lookup in the previous section matters as much for a compounded prescription as for any other.

What does a legitimate GLP-1 prescription involve?

Four parts, in this order, whether the visit happens in an office or online.

1. A licensed prescriber. Who may prescribe is a question of state law; the compounding statute, for example, refers to "a licensed physician or other licensed practitioner authorized by State law to prescribe drugs" (21 U.S.C. 353a(a)(1)). Our state pages link each state's license lookups and record its telehealth rule with the source.
2. An evaluation. The prescriber needs your medical history, your current medications and your goal. Online, this starts with a structured questionnaire and may include a phone or video visit where your state's rules or the physician's judgment call for one.
3. A decision, and a prescription written for you. Only the prescriber decides, and the answer can be no.
4. Dispensing by a state-licensed pharmacy. You should be able to learn the pharmacy's name and find it in your state's license database.

For the online version of this path, including how state telehealth rules differ and how to check a physician's license, see our guide to seeing an online weight loss doctor. For ingredient-specific questions, see our guides to compounded semaglutide and getting tirzepatide.

What happens if the physician says no?

Then there is no prescription, and that is the system working. A prescription is not guaranteed anywhere a licensed prescriber is doing the job. The evaluation exists so that the answer can be no: because of your medical history, a medication you take, or the physician's judgment that another approach suits you.

Three things are worth knowing.

• A decline is a clinical decision, not an obstacle to route around. A seller that offers GLP-1 medication without an evaluation is offering what the FDA warns about.
• Ask what you are charged if the answer is no. At Majesta Health, nothing: the first-month price is charged only after a licensed physician approves treatment, and if treatment is not approved you are not charged at all.
• Take the question to your own doctor. A primary care physician who knows your history can talk through other options, including whether any weight-management medication fits you.

How does the prescription step work at Majesta Health?

Enrollment has not opened yet. Today our assessment places you on an early-access list, and we email you when enrollment opens in your state. No card is requested and nothing is charged. When enrollment opens, the steps are these.

1. You complete the assessment. It asks for your state first, then your goal, height and weight, medical history and current medications.
2. A physician licensed in your state of residence reads your file. The physician may ask for a phone or video visit where your state's rules require one or where the physician asks for one. Every physician is listed with their National Provider Identifier on our care team page, so you can look each one up in the public NPI registry.
3. The physician decides. Medication is prescribed only if a licensed physician determines it is appropriate, and completing the assessment does not guarantee a prescription.
4. Only on approval is anything charged. The first-month price is charged, and the physician's prescription goes to a state-licensed 503A compounding pharmacy, which prepares the medication for you and ships it.

Nothing is charged at checkout: the card is verified with a $0 authorization. The $20 medical consultation fee is included in the first-month price, not charged separately, and if the physician does not approve treatment you pay nothing. To cancel, you email support@majestahealth.com; there is no cancellation fee and no phone call. The pricing page and the billing policy are the documents of record, and practical questions are answered in the help center. Compounded medications are not FDA-approved as final products.

If you want to know whether a prescription GLP-1 medication fits you, the honest first step is a licensed physician's evaluation, not a cart. Our assessment asks for your state first and needs no card. As of September 2026 enrollment has not opened, so finishing it places you on the early-access list and nothing is charged today. When enrollment opens, a physician licensed in your state reads your answers and decides, and completing the assessment does not guarantee a prescription. To see whether we will serve your state, and the telehealth rule that applies there, start with the states page.

What the primary sources say

• Cornell Law School, Legal Information Institute, 21 U.S.C. 353(b)(1) and (b)(4)(A) (accessed September 29, 2026): "is not safe for use except under the supervision of a practitioner licensed by law to administer such drug"; "its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use"; "shall be dispensed only (i) upon a written prescription of a practitioner licensed by law to administer such drug"; "The act of dispensing a drug contrary to the provisions of this paragraph shall be deemed to be an act which results in the drug being misbranded while held for sale."; "fails to bear, at a minimum, the symbol “Rx only”"; (b)(2): "the drug bears a label containing the name and address of the dispenser, the serial number and date of the prescription or of its filling, the name of the prescriber"
• Cornell Law School, Legal Information Institute, 21 CFR 201.100, Prescription drugs for human use (accessed September 29, 2026): "The label of the drug bears: (1) The statement “Rx only”"
• Cornell Law School, Legal Information Institute, 21 U.S.C. 353a(a), Pharmacy compounding (accessed September 29, 2026): "compounded for an identified individual patient based on the receipt of a valid prescription order"; "a licensed pharmacist in a State licensed pharmacy or a Federal facility, or (B) a licensed physician"; "a licensed physician or other licensed practitioner authorized by State law to prescribe drugs"
• U.S. Food and Drug Administration, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (accessed September 29, 2026): "unapproved versions do not undergo FDA’s review for safety, effectiveness and quality before they are marketed."; "Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug."; "Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy."; "does not require a screening and prescription by a licensed doctor before providing medicine"; "does not have a licensed doctor available to answer questions after you receive your medication"; "FDA monitors the internet for fraudulent or unapproved drugs and has issued warning letters to stop the distribution of illegally marketed semaglutide and tirzepatide."; "could contain too little, too much or no active ingredient at all"; "falsely labeled “for research purposes” or “not for human consumption.”"; "These products have been sold directly to consumers for human use with dosing instructions."; "The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health."
• U.S. Food and Drug Administration, BeSafeRx: Your Source for Online Pharmacy Information (accessed September 29, 2026): "FDA’s BeSafeRx campaign helps consumers learn about how to safely buy prescription medicines online."
• U.S. Food and Drug Administration, BeSafeRx: Considering an Online Pharmacy? (accessed September 29, 2026): "Always requires a doctor’s prescription"; "Provides a physical address and telephone number in the United States"; "Has a licensed pharmacist on staff to answer your questions"; "Is licensed with a state board of pharmacy"; "Does not require a doctor’s prescription"; "Offers deep discounts or prices that seem too good to be true"
• U.S. Food and Drug Administration, BeSafeRx: Locate a State-Licensed Online Pharmacy (accessed September 29, 2026): "If your online pharmacy is not listed, you should not use that pharmacy."
• U.S. Food and Drug Administration, Compounding and the FDA: Questions and Answers (accessed September 29, 2026): "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."; "Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities."
• U.S. Food and Drug Administration, Questions and Answers on Dietary Supplements (accessed September 29, 2026): "Under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed."; "Generally, the dietary supplement definition excludes ingredients that are approved as new drugs"
• U.S. Food and Drug Administration, FDA 101: Dietary Supplements (accessed September 29, 2026): "Do not substitute a dietary supplement for a prescription medicine or for the variety of foods important to a healthy diet."
• U.S. Food and Drug Administration, Drugs@FDA through openFDA, application records by active ingredient (semaglutide; tirzepatide) (accessed September 29, 2026): every marketed product returned carries "marketing_status": "Prescription"
• U.S. Food and Drug Administration, openFDA drug label API, GLP-1 receptor agonist class counted by route (accessed September 29, 2026): the routes returned are "SUBCUTANEOUS" and "ORAL"

Every source is listed with its address below.

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider. Compounded medications are not FDA-approved as final products. Medication is prescribed only if a licensed physician determines it is appropriate. Prices are Majesta Health's published prices as of September 2026 and are subject to change.